Plasma samples were obtained from patients entered into the Antwerp and London cohorts who were infected with a variety of HIV-1 clades. Patients were selected for MAb preparation on the basis of the clade of their infecting virus (predominantly non-B clade), and on the ability of their plasma to neutralize, to .80% at a 1/20 dilution, members of a selected panel of Tier 2-type clade A, B, C, CRF02_AG, AE, F and BF viruses in both a PBMCbased infectious primary isolate virus assay [54] and in the TZMbl-based recombinant pseudovirus assay [55] . In some cases only a restricted plasma neutralization analysis was possible due to limiting amounts of patient plasma. Twelve and nine infected donors from the London and Antwerp cohorts respectively were selected for B cell immortalization. Summarized clinical and virological data including HIV-1 clade, viremia, CD4 + T cell counts, therapy and breadth of neutralization are shown in Table S1 .